Nordic cities have qualities to draw on when it comes to greenspace, social inclusion and public health. But they are also segregated, characterised by health-related divides and by differences in accessibility to urban amenities. Without careful consideration the health and well-being of city-dwellers can be negatively influenced in overly densified and congested cities, despite sustainability ambitions.
The SMARTer Greener Cities project aims to develop and test novel tools and processes for explicitly converging social, ecological, and technological systems approaches for improving life in cities.
The MaHoMe project directly addresses migration and integration challenges by examining how migrants make and make sense of home amidst the complex and divergent politics of integration in three host societies: UK, Denmark and Sweden.
The development of smart cities of the future calls for innovative usage of emerging technologies, as well as for novel and effective forms of collaboration across a large number of heterogeneous stakeholders, such as municipal decision-makers, entrepreneurs, and citizens.
The NORDTREAT project will build on the achievements within recent large-scale European initiatives that includes cross-disciplinary collaborations between academia, hospitals, biomedical companies and patient organisations. The overall aim is to improve Inflammatory bowel disease (IBD) patients' prognosis and quality of life by introducing a novel personalized medicine algorithm that is based on recently generated -omics data.
Cancer in children is rare. But cancer remains the disease causing the most deaths in children over the age of 1 year. Most children, who die from cancer, do so because the standard treatment doesn't make their disease disappear (resistant disease) or because the disease returns (relapse of the disease). These children are at a high risk of dying from their cancer and we need to develop new treatments for them.
Globally, the leading cause of years of life lost is ischemic heart disease (IHD). In the EU 13.2 mio. patients are diagnosed with IHD(1) of these 700,000 live in the Nordic countries. IHD causes chest pain, myocardial infarcts, reduced physical capacity and reduces life-expectance. IHD is considered a chronic disease and may progress despite current optimal treatment.
